Moxifloxacin

EXPERIMENTAL DRUGS / POTENTIAL ANTIBIOTIC THERAPIES AGAINST M. ULCERANS

Moxifloxacin

---

CLASS

Fluoroquinolones

---

TARGET PROTEIN

DNA gyrase

---

MECHANISM OF ACTION

Bactericidal activity (They impede DNA replication and transcription by hindering the DNA gyrase-catalyzed super-coiling of double-stranded DNA)

---

DRUG INTERACTION PHASE (APPROVED, INVESTIGATIONAL, EXPERIMENTAL)

Experimental

---

MODE OF ADMINISTRATION

Oral

---

LINK TO PUBMED

https://pubmed.ncbi.nlm.nih.gov/32091697/ 

https://pubmed.ncbi.nlm.nih.gov/16723546/

---

SIMILAR TARGETS IN OTHER SPECIES

DNA gyrase subunit A and DNA topoisomerase 4 subunit A ~ Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)

---

DRUG BANK ID

DB00218

---

EXTERNAL LINKS

Human Metabolome Database HMDB0014363

KEGG Drug D08237

KEGG Compound C07663

PubChem Compound 152946

PubChem Substance 46508509

ChemSpider 134802

BindingDB 50366824

RxNav 139462


ChEBI 63611


ChEMBL CHEMBL32

ZINC ZINC000003826253

Drugs.com Drugs.com Drug Page  https://www.drugs.com/cdi/moxifloxacin-drops.html

PDRhealth PDRhealth Drug Page  http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/ave1540.shtml

Wikipedia Moxifloxacin

---

REFERENCE

Ji, B., Lefrancois, S., Robert, J., Chauffour, A., Truffot, C., & Jarlier, V. (2006). In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrobial Agents and Chemotherapy, 50(6), 1921?1926. https://doi.org/10.1128/AAC.00052-06


Pluschke, G., & R?ltgen, K. (2019). Buruli ulcer: Mycobacterium ulcerans disease. In Buruli Ulcer: Mycobacterium ulcerans Disease. https://doi.org/10.1007/978-3-030-11114-4

---